Shares of Portage Biotech Inc. (PRTG) gained over 10% on Wednesday morning after the company announced that it regained full compliance requirements for continued listing on Nasdaq Capital Market. PRTG is currently trading at $6.28, up $0.58 or 10.06%, on the Nasdaq. The stock opened its trading at...
Portage Biotech Inc. (PRTG) announced Wednesday that it has received formal notice from the Nasdaq Stock Market LLC confirming that the company has regained full compliance with all applicable requirements for continued listing on the Nasdaq Capital Market. The notice, dated June 24, 2025, indicates...
Shares of Portage Biotech Inc. (PRTG) gained over 22% on Monday morning after the clinical-stage immuno-oncology company reported confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor. PRTG is currently trading at $10.38, up $1.93 or 22.84%, on the...
In Monday's pre-market trading, the biotech stocks which are making significant moves are: (as of 8.00 am ET).
Portage Biotech Inc. (PRTG), a clinical-stage immuno-oncology company, has reported new preclinical data confirming the efficacy of its treatment, PORT-7, in a mouse model of mesothelioma. Shares are up over 50% at $12.77 in premarket trading on Monday.
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.